COVID-19 in patients with myasthenia gravis
COVID-19 in patients with myasthenia gravis
复制标题
DOI：
10.1002/mus.26918
复制
发表时间：
2020-05-22
期刊：
影响因子：
3.4
通讯作者：
Guidon, Amanda C.
中科院分区：
文献类型：
--
作者：
Anand, Pria;Slama, Michael C. C.;Guidon, Amanda C.
简介 2019 冠状病毒病 (COVID-19) 已迅速成为全球大流行病，但对其对重症肌无力 (MG) 患者的潜在影响知之甚少。方法我们研究了 2020 年 4 月 1 日至 4 月 30 日至 2020 年 4 月 1 日至 4 月 30 日之间 5 名住院的自身免疫性 MG 患者（4 名具有乙酰胆碱受体抗体，1 名具有肌肉特异性酪氨酸激酶抗体）的 COVID-19 临床病程。气管插管治疗低氧性呼吸衰竭，而一种则需要大量补充氧气。一名先前病情稳定的 MG 患者出现肌无力加重。一名接受托珠单抗治疗的 COVID-19 患者成功拔管。两名患者接受静脉注射免疫球蛋白治疗 MG，未出现血栓栓塞并发症。 讨论 我们的研究结果表明 MG 和 COVID-19 患者的临床病程和结果差异很大。需要进一步的大型研究来定义这一独特人群的最佳实践和结果的决定因素。
Introduction Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic, but little is known about its potential impact on patients with myasthenia gravis (MG).Methods We studied the clinical course of COVID-19 in five hospitalized patients with autoimmune MG (four with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies) between April 1, 2020-April 30-2020.Results Two patients required intubation for hypoxemic respiratory failure, whereas one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID-19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications.Discussion Our findings suggest that the clinical course and outcomes in patients with MG and COVID-19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population.